Press Release | Sirnaomics

29

2022-08

Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

26

2022-08

Sirnaomics Advances GalAhead™-Based RNAi Therapeutics for Treatment of Complement-Related Diseases

23

2022-08

Sirnaomics' 2022 interim results presentation will be held on 31 August 2022

19

2022-08

Sirnaomics becoming a Constituent of Hang Seng Family of Indexes

18

2022-08

Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ

16

2022-08

Sirnaomics Develops Peptide Docking Vehicle (PDoV™) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics

26

2022-07

Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare
for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment

21

2022-06

Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics
based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic:
From Concept to Clinic Symposium

16

2022-06

Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology

30

2022-05

Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment

20

2022-05

Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit

11

2022-05

Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022

04

2022-04

Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis

30

2022-03

RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines

15

2022-03

Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress

23

2022-02

Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

16

2022-02

Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)

09

2022-02

Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors

30

2021-12

Sirnaomics Ltd., the RNA therapeutics biopharmaceutical company with strong presence in both China and the U.S., and the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics, is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”) today.

15

2021-12

Sirnaomics Strengthens Its Development and Manufacturing Leadership with Promotions of Two Biopharma Veterans, Dr. Steven Long and Dr. Edward Wang

22

2021-11

Codex DNA and RNAimmune Announce Collaboration to Optimize Development of Future mRNA Synthesis and Delivery Kits

15

2021-11

Sirnaomics to Present at TIDES Europe 2021

18

2021-10

Sirnaomics to Present STP705, the Company’s Lead Drug Candidate, for the Treatment of Cutaneous Squamous Cell Carcinoma in situ, at the 2021 Fall Clinical Dermatology Conference

21

2021-09

Sirnaomics, Inc. to Present at TIDES USA 2021

14

2021-07

Sirnaomics Doses First Patient in Phase Ⅱ Study of STP705 for Keloid Scar Prevention

06

2021-07

Sirnaomics Receives FDA Approval of IND for Phase Ⅰ Clinical Trial of Systemic RNAi Therapeutic STP707 for Solid Tumor Treatment

01

2021-07

Sirnaomics Secures $107 Million Series E Financing

30

2021-06

Sirnaomics Doses First Patient in Phase Ⅱb Study of STP705 for Treatment of Squamous Cell Skin Cancer

24

2021-06

Sirnaomics Doses First Patient in Phase Ⅰ Clinical Study of STP705 for Treatment of Liver Cancer

16

2021-06

Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase Ⅱb Trial of STP705 Treatment for Skin Squamous Cell Carcinoma

29

2021-04

Sirnaomics Enters Partnership with Walvax Biotechnology to Co-Develop Its Antiviral RNAi Therapeutic Product Candidate STP702

26

2021-04

Sirnaomics Initiates Phase Ⅱb Study Using STP705 for Treatment of Squamous Cell Skin Cancer

21

2021-04

Sirnaomics’ Spin-Off RNAimmune Secures $10 Million Seed Financing to Advance its mRNA-Based Vaccine and Therapeutic Development

18

2021-04

Sirnaomics Initiates Phase Ⅱ Study Using STP705 for Keloid Scar Prevention

03

2021-02

Sirnaomics to Present at Medical Dermatology Summit

17

2021-01

Sirnaomics Announces First Patient Dosed In Phase Ⅱa Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma, Company Expects to Report Initial Clinical Data in 2021

20

2020-12

Sirnaomics Reports Positive Data from Phase Ⅱa Study of STP705 for Treatment of Squamous Cell Skin Cancer

03

2020-12

Sirnaomics to Initiate Phase I Study of STP705 in Treatment of Primary and Metastatic Liver Cancer

22

2020-10

Sirnaomics Sealed US$104 Million Series D Financing to Fund Development of RNAi Therapeutics for Treatment of Cancers, Fibrotic Diseases and Viral Infections

30

2020-08

Sirnaomics Publishes New Preclinical Study Data

27

2020-08

Sirnaomics Publishes Preclinical Study of Novel siRNA-Gemcitabine Conjugate for Advancing RNAi Therapeutics to Treat Multiple Types of Cancers

24

2020-08

RNAimmune Closed Seed Funding of $2.35m for Development of mRNA Therapeutics and Vaccines

20

2020-06

Sirnaomics and Precision NanoSystems Have Formed a Partnership

11

2020-06

Sirnaomics Announces Decision to Spin off RNAimmune to Develop Novel mRNA Therapeutics and Vaccines

09

2020-04

Sirnaomics Announces Positive Topline Results from Interim Analysis of Ongoing Phase II Clinical Trial Evaluating STP705 in Cutaneous Squamous Cell Carcinoma in situ (isSCC)

04

2020-03

Sirnaomics to Present at 5th Annual Oligonucleotide & Precision Therapeutics Congress

19

2020-02

Hunt for New Coronavirus Treatments Includes Gene-Silencing and Monoclonal Antibodies

10

2020-02

Sirnaomics’ siRNA Therapeutic Candidate, STP705, Granted Orphan Drug Designation By US FDA for Treatment of Hepatocellular Carcinoma

28

2020-01

Sirnaomics to develop RNAi-based therapeutics for 2019-nCoV infections

27

2020-01

Coronavirus: AbbVie and Sirnaomics drug candidates explored for Covid-19

24

2020-01

Sirnaomics Advances RNAi-Based Prophylactics and Therapeutics to Battle SARI Caused by 2019-nCoV

13

2020-01

Sirnaomics and Junshi Biosciences Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Tuoyi and RNAi in China and US

07

2020-01

Sirnaomics and Innovent Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US

01

2019-11

Sirnaomics to Present Preclinical STP705 Data Suggesting Reduction in Liver Fibrosis at AASLD Liver Meeting

24

2019-10

Sirnaomics Leadership to Speak at 7th China Renaissance Healthcare and Life Sciences Summit

19

2019-10

Sirnaomics’ President and CEO Patrick Lu Gives Keynote Address at the 7th RNAi China Conference

03

2019-06

Sirnaomics Counts on New RNA Technology to Fuel Wide-Ranging Cancer & Fibrosis Pipeline

16

2019-05

Sirnaomics Publishes Data for Lead Candidate STP705 in Cancer Model as 2019 ASCO Abstract

08

2019-04

Sirnaomics to Present at World Orphan Drug Congress 2019

11

2019-03

Sirnaomics to Present at the 4th Annual OPT: Discovery, Development & Delivery

25

2019-02

Sirnaomics to Present Data Demonstrating STP705 Augmentation of Immune Checkpoint Inhibitors in Live

30

2019-01

Sirnaomics to Present at 2019 BIO CEO & Investor Conference

06

2019-01

CEO Dr. Patrick Lu presents at the CTIC Healthcare Summit

20

2018-12

Sirnaomics Gets FDA Clearance to Start Phase Ⅱ STP705 for NMSC

25

2018-09

Dr. Dmitry Samarsky Joins Sirnaomics Senior Management Team as Chief Technology Officer

20

2018-08

Sirnaomics Cleared to Start First Trial of RNAi Lead in Cancer

16

2018-08

Sirnaomics Oncology IND Receives Green Light from US FDA to Initiate Study for Treatment of CCA

10

2018-08

Sirnaomics Appoints Dr. David Evans as CSO

27

2018-07

Sirnaomics Appoints Dr. Evans as CSO to Lead Preclinical Antifibrosis & Anticancer RNAi Programs

06

2018-06

Sirnaomics Closed Series C1 Financing of US$25 Million and Expands Clinical Programs

03

2018-05

Dr. Steven Long Joins Sirnaomics Senior Management Team as Head of China Clinical Studies

07

2017-12

Sirnaomics Granted Orphan Designation for Treatment of CCA

06

2017-12

Sirnaomics’ STP705 Granted Orphan Designation for Treatment of Cholangiocarcinoma

06

2017-10

Sirnaomics Publishes Results Showing Dual Targeting Effects

01

2017-08

Sirnaomics Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for PSC

15

2017-06

Sirnaomics Advances Leading siRNA Therapeutic Candidate, STP705, for Treatment of Liver Fibrosis

02

2017-06

Sirnaomics Initiates a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705

01

2017-05

Sirnaomics Received IND Approval from CFDA for Its Leading siRNA Therapeutic Candidate, STP705

16

2017-02

Sirnaomics Received Green Light from US FDA for STP705

06

2017-02

Sirnaomics Initiates a Clinical Phase IIa Study of Its siRNA Drug to Treat Hypertrophic Scar

07

2016-11

Sirnaomics Received Green Light from US FDA for a Clinical Phase IIa Study of Its Leading siRNA Drug

04

2016-05

Sirnaomics Raises $10M and Forges a Path to Clinical Development of Its Anti-fibrosis RNAi Drug

21

2016-01

Sirnaomics Files to Begin Trial of Scar-healing Drug in China

05

2015-01

Sirnaomics and Partner Submit IND to CFDA

08

2014-07

Sirnaomics Strengthens Its IP Position for Advancing the Company’s Novel siRNA Therapeutics Programs

25

2014-06

Dr. Patrick Lu Speaks in “The European Summit for Clinical Nanomedicine and Targeted Medicine”

19

2012-12

Sirnaomics Advances Its Novel siRNA Therapeutics Against HPV Infection and Cervical Cancer

28

2012-06

Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field

25

2012-06

Sirnaomics Received NIH SBIR Grant for Developing Its Scarless Wound Healing siRNA Therapeutics

28

2012-02

Dr. Patrick Lu Presents at AsiaTIDES Conference

24

2010-06

Sirnaomics Aims to Move Wound-Healing Drug into Phase I Next Year